(Updated - August 6, 2020 5:51 PM EDT)

Personalis, Inc. (NASDAQ: PSNL) reported Q2 EPS of ($0.29), $0.05 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $16.33 million.

Second Quarter Highlights

• Reported record revenues of $19.5 million in the second quarter of 2020 versus $15.8 million in the second quarter of 2019, an increase of 23%
• A total of 32 customers have placed orders for NeXT as of June 30, 2020, with 6 of those customers placing their first orders in the second quarter of 2020
• Announced a collaboration with Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare disease
• Announced expansion plans into China along with a partnership with Berry Genomics, who will provide services and support to Personalis
• Achieved milestone of completing the 75,000th whole human genome sequenced under the contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP)

“I’m proud to say that we were able to report record revenues once again this quarter, with our team delivering strong execution across both our population sequencing and biopharma businesses, despite the impact from the COVID-19 pandemic, and we continued to see strong ordering levels from both our existing and new customers,” said John West, Chief Executive Officer. “In addition, our recently announced liquid biopsy product will be available to order immediately.”

For earnings history and earnings-related data on Personalis, Inc. (PSNL) click here.

Corporate News Earnings Management Comments

Personalis Reports Second Quarter 2020 Financial ResultsAugust 6, 2020 4:01 PM